comprehensive -WSS

comprehensive

author：focus 2025-10-02 18:46:29 - browse：65763

Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial.

The drug, a daily pill called navacaprant, led to statistically significant improvements over placebo on a measurement of disease severity for patients with moderate to severe major depressive disorder, Neumora said Tuesday. In the eight-week study, the medicine also led to improvements in patient-reported anhedonia, a reduced ability to experience pleasure that often accompanies severe depression.

Navacaprant’s statistically significant benefits came from a pre-specified subset of 100 patients in a study that enrolled 171 people. In the total population, including 71 patients who had mild to moderate disease, navacaprant’s effect on depressive symptoms was numerically superior to placebo but did not reach the threshold of statistical significance, missing the study’s primary endpoint.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： New weight loss drugs work. But how can they best be used?

entertainment

WSS

Chronically ill young patients struggle to find fertility info

Why Congress must ban federal programs from using QALYs

Morgan Health, with ambitious aims, wants you to know it’s still here

JPM: CVS says Medicare Advantage patients are impacting profits

Driven by the pandemic, applicants flood public health schools

Divers poised to search for children washed away in Pennsylvania flash flood

knowledge

comprehensive

focus

Medical records are filled with copy

Tocagen's brain cancer gene therapy trial continues. Investors worry

Walensky prepares to leave CDC — and Congress — behind

Why psychiatrists like me stop taking insurance

After affirmative action ruling, medical educators look to 'holistic review'

I learned firsthand about improving diversity in clinical trials

Apple is now the first public company to be valued at $3 trillion

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

BioMarin wins approval for gene therapy to treat hemophilia A

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

knowledge

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

New weight loss drugs work. But how can they best be used?

EF3 tornado rips through North Carolina amid extreme weather nationwide

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Videos point to link between seizures and unexplained toddler deaths

focus

entertainment

explore

focus